Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease

AstraZeneca1,000 enrolled

Overview

The purpose of this study is to evaluate the impact of gastroesophageal reflux disease (GERD) treatment in primary care setting on symptom control and daily life in symptomatic GERD patients, using both GERD questionnaire and clinical symptoms assessment

A prospective, observational study to describe symptom control and impact on daily life in patients with gastroesophageal reflux disease (GERD)

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Gastroesophageal Reflux Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients known or newly diagnosed with GERD * Patients with typical GERD symptoms as heartburn and regurgitation for ≥2 days in the previous week * Patients, currently not treated with a proton pump inhibitor Exclusion Criteria: * Patients who have been receiving treatment with non-steroidal antiinflammatory drugs within two weeks prior the inclusion in the study * Patients with medical history of surgery of the esophagus, stomach or duodenum * Pregnant or nursing females

Locations (2)

Unnamed facility

Sofia, Bulgaria

Unnamed facility

Varna, Bulgaria

Outcomes

Primary Outcomes

Percent change in intensity and frequency for each of typical GERD symptoms from baseline to week 4-6

Time frame: Day 0 to week 4-6

Changes in GERD questionnaire(GERD-Q) scores from baseline to week 4-6

Time frame: Day 0 to week 4-6

Secondary Outcomes

To evaluate the correlation between GERD-Q scores and symptom scores

Time frame: two times

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.